CLAIMS

1. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the treatment of malignant mesothelioma, wherein lurbinectedin is administered as a monotherapy.

2. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the treatment of malignant mesothelioma, wherein the malignant mesothelioma is malignant pleural mesothelioma.

3. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the treatment of malignant mesothelioma, wherein the malignant mesothelioma is malignant peritoneal mesothelioma.

4. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the treatment of malignant mesothelioma; wherein lurbinectedin treatment excludes treatment with a combination of lurbinectedin and a platinum agent.

5. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the treatment of malignant mesothelioma, wherein lurbinectedin treatment excludes a combination of lurbinectedin and cisplatin.

6. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof as sole chemotherapy agent in the manufacture of a medicament for the treatment of malignant mesothelioma.

7. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the malignant mesothelioma is progressive.

8. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 7, wherein the malignant mesothelioma has progressed from first-line therapy, preferably standard first-line therapy.

9. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 8, wherein the first-line therapy is platinum-pemetrexed chemotherapy.

10. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 9, wherein the platinum-pemetrexed chemotherapy is with surgery.

11. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 9 or claim 10, wherein the first-line therapy also includes radiotherapy.

12. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 8, wherein the first-line therapy is an immunotherapy, preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, or combinations thereof.

13. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 8, wherein the first-line therapy is platinum-pemetrexed chemotherapy and an immunotherapy, preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, of combinations thereof.

14. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 6, wherein lurbinectedin is administered following immunotherapy; preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, or combinations thereof.

15. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 8, wherein the first-line therapy is an anti-angiogenesis therapy.

16. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 15, wherein the anti-angiogenesis therapy is a VEGF inhibitor, such as bevacizumab.

17. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the treatment is a third-line therapy; and wherein the previous lines of therapy may be selected from the therapies in claims 7 to 16, including where the first line therapy is platinum-pemetrexed chemotherapy as claimed in any one of claims 9 to 11, and the second line therapy is immunotherapy.

18. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein lurbinectedin is administered once every one to four weeks, preferably once every three weeks.

19. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein lurbinectedin is administered at a dose of 1 to 5 mg/m^2 body surface area, 2 to 3 mg/m^2 body surface area, about 3 mg/m^2 body surface area, 3 to 3.5 mg/m^2 body surface area, or 3.2 mg/m^2 body surface area.

20. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein lurbinectedin is administered as an infusion, preferably with an infusion time of up to 24 hours, 1 to 12 hours, 1 to 6 hours and most preferably 1 hour.

21. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the patient is additionally treated with radiotherapy.

22. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to claim 18, wherein the radiotherapy is administered prior to or subsequent to administration of lurbinectedin or a pharmaceutically acceptable salt or ester thereof, preferably at least an hour, three hours, five hours, 12 hours, a day, a week, a month, more preferably several months (e.g. up to three months) prior or subsequent to administration of lurbinectedin or a pharmaceutically acceptable salt or ester thereof.

23. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the patient is additionally treated with an anti-emetic, G-CSF and/or GM-CSF.

24. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the patient is additionally treated with G-CSF.

25. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any one of claims 1 to 24, wherein the malignant mesothelioma is epithelioid mesothelioma.

26. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any one of claims 1 to 24, wherein the malignant mesothelioma is sarcomatoid mesothelioma.

27. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any one of claims 1 to 24, wherein the malignant mesothelioma is biphasic mesothelioma.

28. Use of Lurbinectedin or a pharmaceutically acceptable salt or ester thereof according to any preceding claim, wherein the pharmaceutically acceptable salt is selected from the hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate *p*-toluenesulfonate, sodium, potassium, calcium and ammonium salts, ethylenediamine, ethanolamine, *N*,*N*-dialkylenethanolamine, triethanolamine and basic aminoacids salts.

29. A kit comprising lurbinectedin or a pharmaceutically acceptable salt or ester thereof together with instructions for treating malignant mesothelioma.